High ubiquitous mitochondrial creatine kinase expression in hepatocellular carcinoma denotes a poor prognosis with highly malignant potential

International Journal of Cancer

Volumn 134, Issue 9, 2014, Pages 2189-2198

  Uranbileg, Baasanjav ^a   Enooku, Kenichiro ^a   Soroida, Yoko ^a   Ohkawa, Ryunosuke ^a   Kudo, Yotaro ^a   Nakagawa, Hayato ^a   Tateishi, Ryosuke ^a   Yoshida, Haruhiko ^a   Shinzawa, Seiko ^a   Moriya, Kyoji ^a   Ohtomo, Natsuko ^a   Nishikawa, Takako ^a   Inoue, Yukiko ^a   Tomiya, Tomoaki ^a   Kojima, Soichi ^b   Matsuura, Tomokazu ^c   Koike, Kazuhiko ^a   Yatomi, Yutaka ^a   Ikeda, Hitoshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b RIKEN   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ankyrin repeat and suppressor of cytokine signaling box protein 9; hepatocellular carcinoma; prognostic factor; ubiquitous mitochondrial creatine kinase

Indexed keywords

ANKYRIN; MESSENGER RNA; MITOCHONDRIAL CREATINE KINASE; SMALL INTERFERING RNA; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING BOX PROTEIN 9; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CELL DEATH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RADIOFREQUENCY ABLATION; UPREGULATION;

ANKYRIN REPEAT AND SUPPRESSOR OF CYTOKINE SIGNALING BOX PROTEIN 9; HEPATOCELLULAR CARCINOMA; PROGNOSTIC FACTOR; UBIQUITOUS MITOCHONDRIAL CREATINE KINASE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CREATINE KINASE, MITOCHONDRIAL FORM; FEMALE; HUMANS; IMMUNOBLOTTING; LIVER NEOPLASMS; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANSFECTION;

EID: 84896717810     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28547     Document Type: Article

References (40)

1. Umemura T, Ichijo T, Yoshizawa K, et al. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol 2009; 44 Suppl 19: 102-7.
2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
3. Bosch FX, Ribes J, Cleries R, et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9: 191-211.
4. El-Serag HB, Rudolph KL,. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
5. Baffy G, Brunt EM, Caldwell SH,. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012; 56: 1384-91.
6. El-Serag HB, Mason AC,. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50.
7. Nakakura EK, Choti MA,. Management of hepatocellular carcinoma. Oncology (Williston Park) 2000; 14: 1085-98; discussion 98-102.
8. Davila JA, Kramer JR, Duan Z, et al. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology 2013; 57: 1858-68.
9. El-Serag HB, Marrero JA, Rudolph L, et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134: 1752-63.
10. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
11. Bertino G, Ardiri A, Malaguarnera M, et al. Hepatocellualar carcinoma serum markers. Semin Oncol 2012; 39: 410-33.
12. Bertino G, Ardiri AM, Boemi PM, et al. A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma. Panminerva Med 2008; 50: 221-6.
13. Bertino G, Neri S, Bruno CM, et al. Diagnostic and prognostic value of alpha-fetoprotein, des-gamma-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma. Minerva Med 2011; 102: 363-71.
14. Bertino G, Ardiri AM, Calvagno GS, et al. Prognostic and diagnostic value of des-gamma-carboxy prothrombin in liver cancer. Drug News Perspect 2010; 23: 498-508.
15. Malaguarnera G, Paladina I, Giordano M, et al. Serum markers of intrahepatic cholangiocarcinoma. Dis Markers 2013; 34: 219-28.
16. Soroida Y, Ohkawa R, Nakagawa H, et al. Increased activity of serum mitochondrial isoenzyme of creatine kinase in hepatocellular carcinoma patients predominantly with recurrence. J Hepatol 2012; 57: 330-6.
17. Qian XL, Li YQ, Gu F, et al. Overexpression of ubiquitous mitochondrial creatine kinase (uMtCK) accelerates tumor growth by inhibiting apoptosis of breast cancer cells and is associated with a poor prognosis in breast cancer patients. Biochem Biophys Res Commun 2012; 427: 60-6.
18. Kanemitsu F, Kawanishi I, Mizushima J, et al. Mitochondrial creatine kinase as a tumor-associated marker. Clin Chim Acta 1984; 138: 175-83.
19. Pratt R, Vallis LM, Lim CW, et al. Mitochondrial creatine kinase in cancer patients. Pathology 1987; 19: 162-5.
20. Onda T, Uzawa K, Endo Y, et al. Ubiquitous mitochondrial creatine kinase downregulated in oral squamous cell carcinoma. Br J Cancer 2006; 94: 698-709.
21. Patra S, Bera S, SinhaRoy S, et al. Progressive decrease of phosphocreatine, creatine and creatine kinase in skeletal muscle upon transformation to sarcoma. FEBS J 2008; 275: 3236-47.
22. Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4: 1065-7.
23. Moriya K, Nakagawa K, Santa T, et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 2001; 61: 4365-70.
24. Kile BT, Schulman BA, Alexander WS, et al. The SOCS box: a tale of destruction and degradation. Trends Biochem Sci 2002; 27: 235-41.
25. Debrincat MA, Zhang JG, Willson TA, et al. Ankyrin repeat and suppressors of cytokine signaling box protein asb-9 targets creatine kinase B for degradation. J Biol Chem 2007; 282: 4728-37.
26. Kwon S, Kim D, Rhee JW, et al. ASB9 interacts with ubiquitous mitochondrial creatine kinase and inhibits mitochondrial function. BMC Biol 2010; 8: 23.
27. Tokuoka M, Miyoshi N, Hitora T, et al. Clinical significance of ASB9 in human colorectal cancer. Int J Oncol 2010; 37: 1105-11.
28. Ikeda H, Nagashima K, Yanase M, et al. Involvement of Rho/Rho kinase pathway in regulation of apoptosis in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2003; 285: G880-6.
29. Lenz H, Schmidt M, Welge V, et al. Inhibition of cytosolic and mitochondrial creatine kinase by siRNA in HaCaT- and HeLaS3-cells affects cell viability and mitochondrial morphology. Mol Cell Biochem 2007; 306: 153-62.
30. Makuuchi M, Kokudo N, Arii S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008; 38: 37-51.
31. Torzilli G, Minagawa M, Takayama T, et al. Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology 1999; 30: 889-93.
32. Hoshino T, Sakai Y, Yamashita K, et al. Development and performance of an enzyme immunoassay to detect creatine kinase isoenzyme MB activity using anti-mitochondrial creatine kinase monoclonal antibodies. Scand J Clin Lab Invest 2009; 69: 687-95.
33. Omata M, Tateishi R, Yoshida H, et al. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation. Gastroenterology 2004; 127: S159-66.
34. Nishikawa M, Nishiguchi S, Shiomi S, et al. Somatic mutation of mitochondrial DNA in cancerous and noncancerous liver tissue in individuals with hepatocellular carcinoma. Cancer Res 2001; 61: 1843-5.
35. Tamori A, Nishiguchi S, Nishikawa M, et al. Correlation between clinical characteristics and mitochondrial D-loop DNA mutations in hepatocellular carcinoma. J Gastroenterol 2004; 39: 1063-8.
36. Stadhouders AM, Jap PH, Winkler HP, et al. Mitochondrial creatine kinase: a major constituent of pathological inclusions seen in mitochondrial myopathies. Proc Natl Acad Sci USA 1994; 91: 5089-93.
37. Schlattner U, Tokarska-Schlattner M, Wallimann T,. Mitochondrial creatine kinase in human health and disease. Biochim Biophys Acta 2006; 1762: 164-80.
38. Wyss M, Kaddurah-Daouk R,. Creatine and creatinine metabolism. Physiol Rev 2000; 80: 1107-213.
39. Kornacker M, Schlattner U, Wallimann T, et al. Hodgkin disease-derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth inhibition by cyclocreatine treatment independent of apoptosis. Int J Cancer 2001; 94: 513-9.
40. Dang CV, Semenza GL,. Oncogenic alterations of metabolism. Trends Biochem Sci 1999; 24: 68-72.